Collaborative webinar: economic modelling in rare diseases

Mar 2, 2021

Watch the recording

 

It can be challenging to develop an economic model in rare diseases that optimises HTA and reimbursement outcomes. It can be difficult to fully capture the effects of the disease and the benefits of treatment whilst using sufficiently robust data to minimise uncertainty.

This webinar introduces a new approach in which multiple companies collaborate to develop a core economic model and common data set. An approach that aims to optimise HTA and reimbursement outcomes for all new treatments in a rare disease.

Speakers: Prof. Keith Abrams, Prof. John Brazier, Dr. Jill CarltonJosie GodfreyJamie O’Hara, Dr Mark Larkin, PhD, and Juliet Mumby-Croft

JG ZEBRA CONSULTING LTDHCD Economics LtdUniversity of LeicesterUniversity of YorkThe University of SheffieldVitaccessSource Health Economics.

#ProjectHERCULES #rarediseases #heor #healtheconomics #evidencebasedmedicine #pharmaceuticalindustry

More Insights

Modelling requirements for HTA in Europe’s big 5 economies

Modelling requirements for HTA in Europe’s big 5 economies

Written by Oliver Burn, Consultant Health Economist, and Margaret Petrou, Consultant Health Economist Adapting a global economic model for Health Technology Assessment (HTA) submissions in several countries can be challenging, as requirements ... Read more

Advances in artificial intelligence: ChatGPT and the implications for medical writing

Advances in artificial intelligence: ChatGPT and the implications for medical writing

Written by Dom Partridge, Medical Writer As artificial intelligence (AI) technology continues to advance, natural language processing (NLP) models like ChatGPT have gained a lot of attention for their ability to generate human-like text. ... Read more

Obtaining a NICE recommendation for your medical device: a view from the external assessors

Obtaining a NICE recommendation for your medical device: a view from the external assessors

Written by Mark Pennington, Consultant Health Economist A National Institute for Health and Care Excellence (NICE) recommendation can open the door to widespread adoption for a new medical device. But does getting a NICE recommendation require ... Read more

10 steps for a successful global economic model

10 steps for a successful global economic model

Written by Beth Hancock, Senior Consultant Health Economist Pharmaceutical companies often develop global cost-effectiveness and budget impact models, with the aim of adapting them for specific countries. In principle, this is an efficient and ... Read more